.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Teva
McKesson
Chubb
Accenture
Fish and Richardson
US Department of Justice
Colorcon
Merck
Queensland Health

Generated: September 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 018891

« Back to Dashboard
NDA 018891 describes CATAPRES-TTS-3, which is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from two suppliers. Additional details are available on the CATAPRES-TTS-3 profile page.

The generic ingredient in CATAPRES-TTS-3 is clonidine. There are twenty-one drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the clonidine profile page.

Summary for NDA: 018891

Tradename:
3
Applicant:
1
Ingredient:
1
Patents:0
Formulation / Manufacturing:see details

Pharmacology for NDA: 018891

Mechanism of ActionAdrenergic alpha2-Agonists

Suppliers and Packaging for NDA: 018891

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CATAPRES-TTS-1
clonidine
FILM, EXTENDED RELEASE;TRANSDERMAL 018891 NDA Boehringer Ingelheim Pharmaceuticals Inc. 0597-0031 0597-0031-34 4 POUCH in 1 CARTON (0597-0031-34) > 1 PATCH in 1 POUCH > 24 h in 1 PATCH
CATAPRES-TTS-1
clonidine
FILM, EXTENDED RELEASE;TRANSDERMAL 018891 NDA Boehringer Ingelheim Pharmaceuticals Inc. 0597-0032 0597-0032-34 4 POUCH in 1 CARTON (0597-0032-34) > 1 PATCH in 1 POUCH > 24 h in 1 PATCH

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:FILM, EXTENDED RELEASE;TRANSDERMALStrength0.1MG/24HR
Approval Date:Oct 10, 1984TE:ABRLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:FILM, EXTENDED RELEASE;TRANSDERMALStrength0.2MG/24HR
Approval Date:Oct 10, 1984TE:ABRLD:Yes

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:FILM, EXTENDED RELEASE;TRANSDERMALStrength0.3MG/24HR
Approval Date:Oct 10, 1984TE:ABRLD:Yes

Expired Orange Book Patents for NDA: 018891

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim
CATAPRES-TTS-3
clonidine
FILM, EXTENDED RELEASE;TRANSDERMAL018891-003Oct 10, 1984► Subscribe► Subscribe
Boehringer Ingelheim
CATAPRES-TTS-3
clonidine
FILM, EXTENDED RELEASE;TRANSDERMAL018891-003Oct 10, 1984► Subscribe► Subscribe
Boehringer Ingelheim
CATAPRES-TTS-1
clonidine
FILM, EXTENDED RELEASE;TRANSDERMAL018891-001Oct 10, 1984► Subscribe► Subscribe
Boehringer Ingelheim
CATAPRES-TTS-1
clonidine
FILM, EXTENDED RELEASE;TRANSDERMAL018891-001Oct 10, 1984► Subscribe► Subscribe
Boehringer Ingelheim
CATAPRES-TTS-1
clonidine
FILM, EXTENDED RELEASE;TRANSDERMAL018891-001Oct 10, 1984► Subscribe► Subscribe
Boehringer Ingelheim
CATAPRES-TTS-3
clonidine
FILM, EXTENDED RELEASE;TRANSDERMAL018891-003Oct 10, 1984► Subscribe► Subscribe
Boehringer Ingelheim
CATAPRES-TTS-1
clonidine
FILM, EXTENDED RELEASE;TRANSDERMAL018891-001Oct 10, 1984► Subscribe► Subscribe
Boehringer Ingelheim
CATAPRES-TTS-3
clonidine
FILM, EXTENDED RELEASE;TRANSDERMAL018891-003Oct 10, 1984► Subscribe► Subscribe
Boehringer Ingelheim
CATAPRES-TTS-2
clonidine
FILM, EXTENDED RELEASE;TRANSDERMAL018891-002Oct 10, 1984► Subscribe► Subscribe
Boehringer Ingelheim
CATAPRES-TTS-2
clonidine
FILM, EXTENDED RELEASE;TRANSDERMAL018891-002Oct 10, 1984► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
US Department of Justice
Harvard Business School
Covington
Citi
Argus Health
Farmers Insurance
Boehringer Ingelheim
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot